Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298409 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
A Phase 1 study of Small Intestinal Bacterial Overgrowth, sponsored by Envivo Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06298409 is a Phase 1 study of Small Intestinal Bacterial Overgrowth that is actively recruiting participants, run by Envivo Bio. The registered enrollment target is 34 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06298409, a Phase 1 study of Small Intestinal Bacterial Overgrowth, is actively recruiting participants, sponsored by Envivo Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
Conditions Studied
Interventions
- DEVICE CapScan collection capsule
Study Locations (1)
California
- Silicon Valley Gastroenterology - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06298409
The ClinicalTrials.gov registry entry for NCT06298409 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Envivo Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Intestinal Bacterial Overgrowth appearing as the primary indexed condition, and to 1 intervention - of which CapScan collection capsule is the first listed.
NCT06298409 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06298409 about?
NCT06298409 is a clinical study titled "Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®". We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
What is the current status of trial NCT06298409?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2024-02-15. Estimated completion is 2026-02-28.
What conditions does trial NCT06298409 study?
This clinical trial studies the following conditions: Small Intestinal Bacterial Overgrowth.
What interventions are being tested in trial NCT06298409?
The interventions under investigation include: CapScan collection capsule (DEVICE).
Who is sponsoring clinical trial NCT06298409?
This trial is sponsored by Envivo Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298409 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Intestinal Bacterial Overgrowth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.